WASHINGTON, Nov. 28, 2025 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced the following updates regarding tradipitant for motion sickness:
Partial Clinical Hold Re-Review Timeline
Under the collaborative…
WASHINGTON, Nov. 28, 2025 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced the following updates regarding tradipitant for motion sickness:
Partial Clinical Hold Re-Review Timeline
Under the collaborative…
No Comments
Leave a comment Cancel